Evaluation of human coronary vasodilator function predicts future coronary atheroma progression

Sidharta, S.; Baillie, T.; Howell, Stuart; Nicholls, Stephen J.; Montarello, Natalie; Honda, Satoshi; Shishikura, Daisuke; Delacroix, Sinny; Kim, Susan; Beltrame, John F.; Psaltis, Peter J.; Worthley, Stephen G.; Worthley, M.

doi:10.1136/heartjnl-2017-312579

Cited by 3 publications

(1 citation statement)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this method does not allow predicting the development of acute cardiovascular events, visualizing the components of the vessel wall, and evaluating the signs of instability of AP. Besides, in some cases, it cannot provide high-quality visualization, especially in the presence of calcifications or overlapping views [18].…”

Section: The Role Of Imaging Methods In the Diagnostics Of Vulnerable...mentioning

confidence: 99%

Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries

Bikbaeva¹,

Kovalskaya²,

Rodin³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Atherosclerotic plaque (AP) vulnerability can be assessed by coronary artery imaging techniques. Modern lipid-lowering therapy (LLT) has a stabilizing effect on the AP and reduces the likelihood of progression of vascular remodeling. Methods: Databases searched comprised PubMed, and the Web of Science up to April 2023. In total, 8 relevant articles were selected, and all of them are original clinical studies. Results Based on the results of ODISSEY-J-IVUS, there was a decrease in the percentage change in the normalized total volume of AP by 3.1% in the monotherapy group and by 4.8% in the combined LLT group (p = 0.23). According to GLACOV study normalized total atheroma volume decreased by 0.9 mm3 in the placebo group and by 5.8 mm3 in the evolocumab group (95% CI -7.3 -2.5; p<0.001). Plaque regression was observed in 64.3% of patients receiving evolocumab versus 47.3% of those on placebo. The dynamics of the minimum thickness of the fibrous cap varied within 18.0-62.67 microns while on combined LLT and 13.2-33.19 microns on monotherapy (PACMAN-AMI, Gao F). In the HUYGENS study, a lipid arc regression of 57.5° was obtained on combined LLT and by 31.4° with the statin alone. Conclusion: significant progress in the development of cardiovascular imaging has made it possible to expand our understanding of the morphology of AP, the features of coronary vessel remodeling, and the development of acute cardiovascular complications.

show abstract

Section: The Role Of Imaging Methods In the Diagnostics Of Vulnerable...mentioning

confidence: 99%

Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries

Bikbaeva¹,

Kovalskaya²,

Rodin³

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

Role of local coronary blood flow patterns and shear stress on the development of microvascular and epicardial endothelial dysfunction and coronary plaque

Siasos

Tsigkou

Zaromitidou

et al. 2018

Current Opinion in Cardiology

View full text Add to dashboard Cite

Detection and Stabilisation of Vulnerable Plaques in the Coronary Arteries

Bikbaeva,

Kovalskaya,

Rodin

et al. 2024

J Asian Pac Soc Cardiol

View full text Add to dashboard Cite

Vulnerable atherosclerotic plaques (AP) can be assessed by coronary artery imaging techniques. Intravascular ultrasound allows real-time assessment of the longitudinal and transverse dimensions of the vessel, the severity of its remodelling, and the size and structure of the AP. The resolution of optical coherent tomography makes it possible to accurately identify vulnerable APs according to the following characteristic parameters: a large necrotic nucleus, a thin fibrous capsule, neoangiogenesis and inflammatory changes in the AP cap. Percent atheroma volume, total atheroma volume, maximum lipid core burden index within 4 mm, minimal fibrous cap thickness, maximum lipid arc, lipid length and macrophage grade are the main characteristics of vulnerable AP. Lipid-lowering therapy (LLT) has a stabilising effect on AP. Databases searched were PubMed and Web of Science up to April 2023. In total, eight relevant articles (original clinical studies) were selected. In the ODISSEY J-IVUS study, there was a decrease of total AP volume by 3.1% in the monotherapy group and 4.8% in the combined LLT group (p=0.23). In the GLAGOV trial, atheroma volume decreased by 0.9 mm3 in the placebo group and 5.8 mm3 in the evolocumab group (p<0.001). Plaque regression was observed in 64.3% of patients in the evolocumab group and 47.3% in the placebo group. The dynamics of the minimum thickness of the fibrous cap varied within 18.0–62.67 µm on combined LLT and 13.2–33.19 µm on monotherapy (PACMAN-AMI). Regression of the lipid arc was also observed in the HUYGENS study. The development of cardiovascular imaging has made it possible to expand understanding of the morphology of vulnerable AP.

show abstract

Evaluation of human coronary vasodilator function predicts future coronary atheroma progression

Abstract: ACTRN12612000594820, Post-results.

Cited by 3 publications

References 30 publications

Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries

Detection and Stabilization of Vulnerable Plaques in the Coronary Arteries

Role of local coronary blood flow patterns and shear stress on the development of microvascular and epicardial endothelial dysfunction and coronary plaque

Detection and Stabilisation of Vulnerable Plaques in the Coronary Arteries

Contact Info

Product

Resources

About